Sentinel lymph node (SLN) mapping is a valuable and crucial diagnostic procedure in staging malignancies. We compared two non-invasive techniques, near-infrared (NIR) fluorescence imaging and contrast-enhanced ultrasound (CEUS), to identify the SLNs in three superficial anatomical regions in an animal model.
| INTRODUCTION
The sentinel lymph node (SLN) is defined as the first lymph node (LN) that receives drainage from a specific anatomical region. 1 It is also defined as the first LN that tumour cells reach after detaching from the primary tumour. 2 The SLN acts as a first reservoir from where metastatic tumour cells can further spread through efferent lymphatic vessels, the thoracic duct, and ultimately, the venous system. 3 Furthermore, lymphangiogenic factors released by the primary tumour can induce lymphangiogenesis in and around the tumour. 1, 4 Under these conditions, the lymphatic network can alter, and novel lymphatic tracts can bring dislodged tumour cells to other LNs than those expected. 5, 6 The identification of the SLN, and of metastatic tumour cells within it, will play a major role in directing adjuvant treatment and in determining an accurate prognosis. 2, 7 In human medicine, SLN mapping and SLN biopsy are performed in a variety of cancer types that are prone to lymphatic spread (eg, breast cancer and melanoma). Techniques that are currently accepted as the gold standard include peri-tumoural injection of 99m Tc-labelled radio-colloids followed by the injection of blue dyes. 8, 9 The combina-time information regarding the exact location of afferent lymphatics and the SLN. [19] [20] [21] NIR fluorescence imaging systems utilize a light spectrum with wavelengths between 650 and 850 nm. In this spectrum, autofluorescence is limited and the absorption of light by intrinsic tissue, for example, water and haemoglobin, is severely reduced.
Consequently, deeper penetration into the tissues compared to white light becomes feasible (up to 10 mm). 22, 23 Fluorophores that are excited and fluoresce in the NIR spectrum can be used as optical probes for NIR fluorescence imaging. Indocyanine Green (ICG) is considered as a safe and effective NIR fluorescent probe, useful for preand intraoperative imaging of the lymphatic system. 11 In human oncology, SLN mapping using NIR fluorescence imaging has been validated in breast, cervical, and gastric malignancies and in malignant melanomas. 21, [24] [25] [26] [27] Contrast-enhanced ultrasound (CEUS) is another novel real-time, non-invasive and non-ionizing imaging modality that is gaining attention in human SLN mapping. 28 Microbubbles (MB), composed of a high-molecular weight gas enclosed by a lipid shell, act as a sonographic contrast agent. 29 When injected subdermally, MB enter the lymphatic system and drain to the SLNs within seconds to minutes (depending on the distance between the injection site and SLN). 30 In human medicine, several studies showed that CEUS can be used for the detection of SLNs in breast cancer patients. 16, 29, 31, 32 Until now, SLN mapping is lagging behind in companion animal oncology and there is no gold standard established. 33 , 34 Yet, various techniques have been studied in dogs, so far merely from a translational perspective [35] [36] [37] [38] or for lymphatic charting in healthy dogs. 30, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] There is one published report on the use of CEUS for SLN mapping after local contrast injection in dogs with head and neck neoplasias. 48 A few research groups recently published successful SLN mapping by contrast-enhanced computed tomography (CT) lymphography after local contrast injection in dogs with head and neck, perianal and mammary gland neoplasias. [49] [50] [51] [52] However, transcutaneous NIR fluorescence imaging as a modality for SLN mapping has not been investigated in dogs so far.
We hypothesize that NIR fluorescence imaging and CEUS are two 
| MATERIALS AND METHODS
The study protocol adhered to the European Communities Council Directive (2010/63/EU). Six healthy female laboratory Beagles were included (Table 1) . Dogs were considered as healthy based on a thorough physical examination, haematology and biochemistry profiles.
The complete right mammary chain, right popliteal, tarsal and interdigital region were gently clipped 2 days before the trial to prevent false-positive fluorescent signals deriving from irritation because of clipping. The day of the trial, a 22 Gauge intravenous (IV) catheter was inserted in the cephalic vein. Sedation was provided by the IV administration of butorphanol (Dolorex, MSD, Brussels, Belgium) at 0.4 mg/kg. In intact dogs, a vaginal smear and cytology were performed to assess the reproduction status.
| Transcutaneous NIR fluorescence imaging
Indocyanine Green (ICG-PULSION, PULSION Medical Systems SE, Feldkirchen, Germany), 25 mg dark green powder per vial, was stored in a dark container at room temperature. Immediately before subdermal injection, ICG was dissolved in 5 mL sterile aqua ad iniectabilia (B. Braun Melsungen AG, Germany). Subsequently, 4.5 mL aqua ad iniectabilia was mixed with 0.5 mL dissolved ICG (5 mg/mL), yielding a final concentration of 0.5 mg/mL.
Fluorescence imaging was performed using a Fluobeam 800 camera device (Fluoptics, Grenoble, France). This portable system consists of two parts: a control unit with a laser source emitting at 780 nm and a power supply for light-emitting diodes (LEDs), next to an optical head with a highly sensitive charge-coupled device camera and white
LEDs for the illumination of the field of view. The laser beam is fibre- Consequently, the site for the second injection was marked 15 mm cranial to the nipple of the right second mammary gland. The injection and imaging protocol was repeated as described above.
Lastly, the site for the third injection was marked on the skin between the third and the fourth digit of the right-hind leg. The injection and imaging protocol was repeated as described above. The complete protocol has been executed in an identical order all dogs.
| Conventional B-mode ultrasound and CEUS
Once the NIR fluorescence imaging procedure was finalized, the ultra- 
| Data analysis
Descriptive statistics were used. Normal distribution of continuous data (age and weight) was assessed using a Sharpiro-Wilk's test. The NIR fluorescent images were analysed using a qualified quantification program (ImageJ). Contrast intensities were measured in the different regions (injection site, afferent lymphatics, SLN and surroundings) at all time intervals p.i.
Regarding CEUS, the ease of identification of the afferent lymphatic tract and the SLNs was assessed during the imaging procedure.
The filling states of the LNs were evaluated on the acquired movie clips and images.
| RESULTS
The baseline characteristics of the experimental dogs and the time to the first visualization of the SLNs by NIR fluorescence are summarized in Table 1 . The number and characteristics of the LNs assessed by NIR fluorescence imaging, B-mode conventional US, and CEUS are summarized in Table 2 . Maximum intensities of the afferent lymphatic tract and the SLNs depended on the depth of the LN and on manipulations of the skin.
When the skin was manipulated by means of gentle pressure or movement, the signal intensified in all dogs at all occasions. In general, an exposure of 75 ms resulted in the most optimal signal-to-background ratio images of the afferent lymphatic tract and the SLNs. However, a few cases needed an exposure of 150 ms rather than 75 ms to obtain a decent contrast; those were indicated in Table 2 .
In all dogs and in all regions, fluorescence images taken with pressure on the skin using plexy glass resulted in a sharper image when compared to images taken without pressure. However, this increase in subjective sharpness did not correlated to an increase in the intensity of the fluorescent signals assessed by objective quantification measurements. Abbreviations: A, anestrus; N, neutered; P, pro-estrus.
Two days p.i., the region of the injection site still emitted a signal equal to the intensity measured at the injection site 2 minutes p.i. Six days p.i., the region of the injection site still emitted a signal but with an intensity that was 74% lower compared to the intensity measured 2 minutes p.i. Two and 6 days p.i., the SLNs emitted a signal equal to the base line values measured before the injection of the contrast, rendering identification of the LN no longer feasible. 
| Inguinal region

| Popliteal region
Transcutaneous LN mapping of the SLN in the popliteal region was successful in all 6 dogs ( Figure 3 ). All popliteal LNs were situated in the popliteal fossa, caudal to the stifle joint, in the fat depot between the medial border of the biceps femoris muscle and the lateral border In dog 4, a second popliteal LN was visualized after 25 minutes. In this case, an interdigital spread of the contrast was also noticed 10 minutes p.i. In dog 5, the presence of a second popliteal LN was suspected 30 minutes p.i. but, with gentle pressure applied to the skin overlying this spot, the contrast clearly accumulated in only one LN. In 3 dogs (dogs 2, 4 and 6), afferent lymphatic tracts bilateral of the saphenous vein captured contrast and delineated the vein. In none of the dogs, an efferent lymphatic tract spreading beyond the popliteal region was identified.
| Conventional B-mode US and CEUS
| General findings
The size of the LNs and the differences between the depth of the LNs assessed by conventional B-mode US with and without pressure is specified in Table 2 . Sentinel lymph node mapping using CEUS was feasible in all 3 regions in all 6 dogs. In all cases, the SLNs were identified within 2 minutes p.i. In all regions, the location of the LNs was identical to the location identified by NIR fluorescence imaging. 
| Inguinal region
| Axillary region
The afferent lymphatic tract and both axillary and accessory axillary
SLNs were identified by CEUS in 4 dogs (dogs 1, 2, 5 and 6). Five LNs In these cases, one LN was completely filled (dog 4) and one partially filled (dog 3).
The afferent lymphatic vessels were often difficult to visualize.
Retrograde scanning, starting from the SLN, was necessary for the visualization of the afferent lymphatic tract in one dog (dog 3). Uptake of MB by the efferent lymphatic vessels starting from the SLN(s) was visualized in 2 dogs (dog 2 and 4).
| Popliteal region
In the tarsal region, visualization of the afferent lymphatic tracts was In one dog (dog 1), that had pre-existing chronic keratosis, a hard nodule with a diameter of 11 mm was noticed at the injection site caudal to the fourth nipple 2 days p.i, that had disappeared by day 6 p.i. In none of the other dogs, dermatological conditions were present at the time of the trial and no inflammatory reactions nor adverse events were noticed in the p.i. period.
| DISCUSSION
To the best of our knowledge, this proof-of-concept study is the first in vivo trial that describes transcutaneous SLN mapping by NIR fluorescence imaging for pre-operative surgical planning in dogs. In 17 out of 18 occasions that were imaged, NIR fluorescence imaging was able to identify the SLNs. In addition, we confirmed the value of CEUS as an imaging tool for SLN mapping in dogs, with successful imaging in all regions in all dogs (18/18) . Both techniques appeared to be safe; subdermal administration of ICG or MB did not induce any adverse events in any of the dogs.
Our objective was to identify SLNs through the intact skin in healthy dogs as a model for SLN mapping in cancer patients. We aimed for imaging modalities that have potential to be incorporated into daily clinical practice and that could overcome the drawbacks of the previously mentioned techniques tested for SLN mapping. Three studies report that the use of NIR fluorescence imaging for SLN mapping in dogs as a translational model for a variety of human abdominal cancers. The first study described successful SLN mapping using the non-targeted contrast agent IRDye800CW (LI-COR; Lincoln, Nebraska), conjugated with human serum albumin, in healthy dogs and in dogs with naturally occurring malignancies of the urinary bladder wall. 54 Another study reported SLN mapping of the prostate using the radiolabelled targeted contrast agent tilmanocept, in healthy dogs as a model for prostate cancer. 55 The most recent study demonstrated successful SLN mapping of the stomach using ICG and IRDye 800CW labelled to poly-γ-glutamic acid and pullulan-cholesterol nanogels, We have demonstrated that for transcutaneous NIR fluorescence imaging, the time interval between injection and uptake of ICG by the SLN and the contrast intensity after subdermal injection is dependent on the injection site, the depth of the SLNs, and, the pressure applied to the skin. In addition, the visualization of the SLN can be highly dependent on the position of the patients (in respect) to the camera and the distance of the camera to the skin. Especially in the axillary region, the position can be critical for a correct visualization. When the distance to the skin is not correct, the images will be blurred. All Regarding CEUS, our trial illustrated the successful and rapid migration of MB after subdermal injection, which is similar to the outcome reported in previous studies. 30, 44, 47 Another imaging modality that is recently gaining attention for SLN mapping in dogs with cancer is contrast CT lymphography. [49] [50] [51] [52] Where NIR fluorescence imaging is limited to the detection of superficially located LNs, contrast CT lymphography allows detection of LNs that are located deeper than several cm under the body surface. Interestingly, one research group reported that CT lymphography was capable of predicting the presence of lymphatic metastases, 49 which is currently not feasible with NIR fluorescence imaging using the FDAapproved non-targeted fluorescent probe. However, performing CT requires the dogs to be heavily sedated or anesthetised and involves exposure to radiation. Similar to the techniques investigated in this study, the impact of correct patient positioning to obtain minimal pressure on the lymphatics was mentioned in 2 studies as an important factor for successful LN mapping with CT lymphography. 50, 51 A limitation of the study is the limited number of dogs and the lack of regional dissection for LN removal, directed by ethical con- 
